A study of breast cancer survivors’ cognitive performance before and after chemotherapy sheds light on the problem of cancer-related cognitive impairment.
A study of breast cancer survivors’ cognitive performance before and after chemotherapy sheds light on the problem of cancer-related cognitive impairment. Researchers conducted a longitudinal study of breast cancer patients who were treated in community oncology clinics, and an age-matched noncancer control group, by testing their cognitive functioning at 3 points. The results were published in the Journal of Clinical Oncology (JCO).
The study recruited 367 patients and controls who were tested prior to initiating treatment for the cancer patients, to establish a baseline. Participants were tested using the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), which is a tool “that was created specifically to assess cognitive challenges identified by patients with cancer.”
This test assessed participants’ perceived cognitive impairment and abilities, the impact of cognitive impairment on their quality of life, and cognitive impairment perceived by others. A lower score indicated decreased cognitive functioning. Participants were also tested to measure their baseline levels of anxiety, depressive symptoms, and reading ability as a proxy for cognitive reserve. They took the same tests after the cancer patients finished chemotherapy and then 6 months after that.
Patients with breast cancer had lower FACT-Cog scores than the controls, even before their treatment began. Post-chemotherapy, these patients reported significantly greater cognitive complaints than the controls, as their scores decreased and the controls’ scores remained level. In the follow-up test, breast cancer survivors reported slight improvements in cognitive functioning, but their scores remained significantly below the baseline level.
Over the entire study period from pre-chemotherapy to the 6-month follow-up, 36.5% of the breast cancer patients demonstrated a decline in FACT-Cog scores, compared with just 13.6% of the controls. Higher levels of anxiety and depression were predictive of lower FACT-Cog scores, as were higher cognitive reserve levels, but there was no link to educational attainment.
The study authors wrote that the results indicated that self-reported cognitive impairment “is a substantial and pervasive problem for patients with breast cancer who received chemotherapy,” and that these patients are likely predisposed to cognitive impairment due to “a combination of demographic, medical, and psychological factors.”
Cognitive impairment could be lessened, they wrote, with more successful management of anxiety and depression during chemotherapy. The results also underscored the importance of cognitive reserve, rather than education status, as a protective factor against potential impairment. The researchers plan to conduct a follow-up study with the breast cancer patients 2 years after treatment ends.
A potential solution to cancer-related cognitive impairment, also called “chemo brain,” was discussed in a JCO study that evaluated the effects of a Web-based cognitive rehabilitation program in a group of cancer patients with cognitive impairment. The participants who received the Insight intervention had significantly better FACT-Cog scores than the control group, both right after the 15-week program and 6 months later.
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America
May 6th 2024CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
Read More
Shelly Lanning on How Employers Can Reduce Costs by Bridging Gaps in Women's Health Care
May 3rd 2024In a presentation at the Greater Philadelphia Business Coalition on Health Women’s Health Summit, Shelly Lanning, cofounder and president of Visana Health, addressed the need for comprehensive approaches in women’s health care and their coverage options.
Read More